{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T05:10:59Z","timestamp":1792300259286,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,4,1]],"date-time":"2019-04-01T00:00:00Z","timestamp":1554076800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Archives of Cardiovascular Diseases"],"published-print":{"date-parts":[[2019,4]]},"DOI":"10.1016\/j.acvd.2019.01.002","type":"journal-article","created":{"date-parts":[[2019,2,27]],"date-time":"2019-02-27T22:21:50Z","timestamp":1551306110000},"page":"278-287","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":95,"title":["Fabry disease in cardiology practice: Literature review and expert point of view"],"prefix":"10.1016","volume":"112","author":[{"given":"Albert","family":"Hag\u00e8ge","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"R\u00e9ant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilbert","family":"Habib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibaud","family":"Damy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Barone-Rochette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Soulat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2677-3389","authenticated-orcid":false,"given":"Erwan","family":"Donal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique P.","family":"Germain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.acvd.2019.01.002_bib0255","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1086\/504601","article-title":"High incidence of later-onset fabry disease revealed by newborn screening","volume":"79","author":"Spada","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.acvd.2019.01.002_bib0260","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.acvd.2019.01.002_bib0265","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/mgg3.389","article-title":"Phenotypic characteristics of the p.Asn215Ser (p.N215S) GLA mutation in male and female patients with Fabry disease: A multicenter Fabry Registry study","volume":"6","author":"Germain","year":"2018","journal-title":"Mol Genet Genomic Med"},{"key":"10.1016\/j.acvd.2019.01.002_bib0270","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0275","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1136\/heartjnl-2015-307472","article-title":"Adult patients with Fabry disease: what does the cardiologist need to know?","volume":"101","author":"Hagege","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0280","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1093\/eurheartj\/ehm153","article-title":"Cardiac manifestations of Anderson-Fabry disease: results from the international Fabry outcome survey","volume":"28","author":"Linhart","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0285","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/j.1445-5994.2008.01669.x","article-title":"Cardiovascular testing in Fabry disease: exercise capacity reduction, chronotropic incompetence and improved anaerobic threshold after enzyme replacement","volume":"38","author":"Lobo","year":"2008","journal-title":"Intern Med J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0290","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/jmg.2008.065904","article-title":"Natural course of Fabry disease: changing pattern of causes of death in FOS - Fabry Outcome Survey","volume":"46","author":"Mehta","year":"2009","journal-title":"J Med Genet"},{"key":"10.1016\/j.acvd.2019.01.002_bib0295","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1097\/GIM.0b013e3181bb05bb","article-title":"Life expectancy and cause of death in males and females with Fabry disease: findings from the Fabry Registry","volume":"11","author":"Waldek","year":"2009","journal-title":"Genet Med"},{"key":"10.1016\/j.acvd.2019.01.002_bib0300","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1136\/heartjnl-2014-306278","article-title":"Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease","volume":"101","author":"Talbot","year":"2015","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0305","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1016\/j.jacc.2010.11.018","article-title":"Cardiovascular events in patients with fabry disease natural history data from the fabry registry","volume":"57","author":"Patel","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0310","doi-asserted-by":"crossref","first-page":"6421","DOI":"10.1093\/eurheartj\/ehx493.P6421","article-title":"Role of sudden cardiac death as end-stage complication in Fabry disease cardiomyopathy: Impact of primary and secondary prophylactic ICD therapy on long-term outcome","volume":"38","author":"Oder","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0315","article-title":"Ventricular arrhythmia and sudden cardiac death in Fabry disease: a systematic review of risk factors in clinical practice","author":"Baig","year":"2017","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2019.01.002_bib0320","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1136\/heartjnl-2016-310138","article-title":"Relationship between aetiology and left ventricular systolic dysfunction in hypertrophic cardiomyopathy","volume":"103","author":"Rosmini","year":"2017","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0325","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1136\/hrt.2010.200188","article-title":"Screening patients with hypertrophic cardiomyopathy for Fabry disease using a filter-paper test: the FOCUS study","volume":"97","author":"Hagege","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0330","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1136\/heartjnl-2011-300364","article-title":"Prevalence of Anderson-Fabry disease in patients with hypertrophic cardiomyopathy: the European Anderson-Fabry Disease survey","volume":"97","author":"Elliott","year":"2011","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0335","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1016\/j.jacc.2007.06.062","article-title":"Prevalence of fabry disease in a cohort of 508 unrelated patients with hypertrophic cardiomyopathy","volume":"50","author":"Monserrat","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0340","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2017.09.010","article-title":"Identification of Fabry Disease in a Tertiary Referral Cohort of Patients with Hypertrophic Cardiomyopathy","volume":"131","author":"Maron","year":"2018","journal-title":"Am J Med"},{"key":"10.1016\/j.acvd.2019.01.002_bib0345","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/cge.12613","article-title":"X-chromosome inactivation in female patients with Fabry disease","volume":"89","author":"Echevarria","year":"2016","journal-title":"Clin Genet"},{"key":"10.1016\/j.acvd.2019.01.002_bib0350","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.ymgme.2011.07.014","article-title":"The use of dried blood spot samples in the diagnosis of lysosomal storage disorders\u2013current status and perspectives","volume":"104","author":"Reuser","year":"2011","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.acvd.2019.01.002_bib0355","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccep.2015.03.014","article-title":"Arrhythmias in Fabry cardiomyopathy","volume":"7","author":"Acharya","year":"2015","journal-title":"Card Electrophysiol Clin"},{"key":"10.1016\/j.acvd.2019.01.002_bib0360","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.ymgme.2018.02.014","article-title":"Fabry disease revisited: Management and treatment recommendations for adult patients","volume":"123","author":"Ortiz","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.acvd.2019.01.002_bib0365","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.amjcard.2016.04.033","article-title":"Usefulness of an Implantable Loop Recorder to Detect Clinically Relevant Arrhythmias in Patients With Advanced Fabry Cardiomyopathy","volume":"118","author":"Weidemann","year":"2016","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0370","doi-asserted-by":"crossref","first-page":"e4996","DOI":"10.1097\/MD.0000000000004996","article-title":"Cardiac device implantation in Fabry disease: A retrospective monocentric study","volume":"95","author":"Sene","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.acvd.2019.01.002_bib0375","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.amjcard.2014.06.019","article-title":"Relation of burden of myocardial fibrosis to malignant ventricular arrhythmias and outcomes in Fabry disease","volume":"114","author":"Kramer","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0380","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1093\/eurheartj\/ehp588","article-title":"Cardiovascular manifestations of Fabry disease: relationships between left ventricular hypertrophy, disease severity, and alpha-galactosidase A activity","volume":"31","author":"Wu","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0385","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.amjcard.2006.07.088","article-title":"Significance of asymmetric basal posterior wall thinning in patients with cardiac Fabry's disease","volume":"99","author":"Kawano","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0390","doi-asserted-by":"crossref","DOI":"10.1016\/j.echo.2018.01.016","article-title":"Echocardiographic Assessment of Patients with Fabry Disease","volume":"31","author":"Yeung","year":"2018","journal-title":"J Am Soc Echocardiogr"},{"key":"10.1016\/j.acvd.2019.01.002_bib0395","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1093\/ejechocard\/jer109","article-title":"Usefulness of tissue Doppler on early detection of cardiac disease in Fabry patients and potential role of enzyme replacement therapy (ERT) for avoiding progression of disease","volume":"12","author":"Zamorano","year":"2011","journal-title":"Eur J Echocardiogr"},{"key":"10.1016\/j.acvd.2019.01.002_bib0400","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12968-016-0233-6","article-title":"Cardiovascular magnetic resonance demonstration of the spectrum of morphological phenotypes and patterns of myocardial scarring in Anderson-Fabry disease","volume":"18","author":"Deva","year":"2016","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.acvd.2019.01.002_bib0405","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1080\/10976640600605002","article-title":"The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease","volume":"8","author":"Moon","year":"2006","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.acvd.2019.01.002_bib0410","doi-asserted-by":"crossref","first-page":"2554","DOI":"10.1016\/j.jacc.2016.09.943","article-title":"Later onset Fabry disease, cardiac damage progress in silence: experience with a highly prevalent mutation","volume":"68","author":"Hsu","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0415","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.jcmg.2011.01.020","article-title":"Differences in Fabry cardiomyopathy between female and male patients: consequences for diagnostic assessment","volume":"4","author":"Niemann","year":"2011","journal-title":"JACC Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2019.01.002_bib0420","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1136\/heartjnl-2015-308494","article-title":"Cardiac involvement in genotype-positive Fabry disease patients assessed by cardiovascular MR","volume":"102","author":"Kozor","year":"2016","journal-title":"Heart"},{"key":"10.1016\/j.acvd.2019.01.002_bib0425","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1161\/CIRCIMAGING.112.000070","article-title":"Identification and assessment of Anderson-Fabry disease by cardiovascular magnetic resonance noncontrast myocardial T1 mapping","volume":"6","author":"Sado","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2019.01.002_bib0430","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1161\/CIRCIMAGING.113.000482","article-title":"T(1) mapping with cardiovascular MRI is highly sensitive for Fabry disease independent of hypertrophy and sex","volume":"6","author":"Thompson","year":"2013","journal-title":"Circ Cardiovasc Imaging"},{"key":"10.1016\/j.acvd.2019.01.002_bib0435","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s12968-017-0389-8","volume":"19","author":"Messroghli","year":"2017","journal-title":"J Cardiovasc Magn Reson"},{"key":"10.1016\/j.acvd.2019.01.002_bib0440","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1093\/eurheartj\/ehp426","article-title":"Aortic remodelling in Fabry disease","volume":"31","author":"Barbey","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.acvd.2019.01.002_bib0445","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.jacc.2011.03.020","article-title":"Exercise-induced left ventricular outflow tract obstruction in symptomatic patients with Anderson-Fabry disease","volume":"58","author":"Calcagnino","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0450","doi-asserted-by":"crossref","first-page":"e002839","DOI":"10.1161\/JAHA.115.002839","article-title":"High-Sensitivity Troponin: A Clinical Blood Biomarker for Staging Cardiomyopathy in Fabry Disease","volume":"5","author":"Seydelmann","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.acvd.2019.01.002_bib0455","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjcard.2012.08.055","article-title":"Role of serum N-terminal pro-brain natriuretic peptide measurement in diagnosis of cardiac involvement in patients with anderson-fabry disease","volume":"111","author":"Coats","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0460","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jacc.2016.05.090","article-title":"Genetic Screening of Anderson-Fabry Disease in Probands Referred From Multispecialty Clinics","volume":"68","author":"Favalli","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0465","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1093\/europace\/eur267","article-title":"Incidence and predictors of anti-bradycardia pacing in patients with Anderson-Fabry disease","volume":"13","author":"O\u2019Mahony","year":"2011","journal-title":"Europace"},{"key":"10.1016\/j.acvd.2019.01.002_bib0470","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/joim.12077","article-title":"Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications","volume":"274","author":"Weidemann","year":"2013","journal-title":"J Intern Med"},{"key":"10.1016\/j.acvd.2019.01.002_bib0475","first-page":"81","article-title":"Cardiac transplantation for Fabry's disease","volume":"14","author":"Cantor","year":"1998","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.acvd.2019.01.002_bib0480","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1111\/j.1540-8175.2005.03191.x","article-title":"Fabry disease: percutaneous transluminal septal myocardial ablation markedly improved symptomatic left ventricular hypertrophy and outflow tract obstruction in a classically affected male","volume":"22","author":"Magage","year":"2005","journal-title":"Echocardiography"},{"key":"10.1016\/j.acvd.2019.01.002_bib0485","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.ymgme.2018.06.004","article-title":"European expert consensus statement on therapeutic goals in Fabry disease","volume":"124","author":"Wanner","year":"2018","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.acvd.2019.01.002_bib0490","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1038\/gim.2013.53","article-title":"Analysis of left ventricular mass in untreated men and in men treated with agalsidase-beta: data from the Fabry Registry","volume":"15","author":"Germain","year":"2013","journal-title":"Genet Med"},{"key":"10.1016\/j.acvd.2019.01.002_bib0495","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1161\/CIRCULATIONAHA.108.794529","article-title":"Long-term effects of enzyme replacement therapy on fabry cardiomyopathy: evidence for a better outcome with early treatment","volume":"119","author":"Weidemann","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.acvd.2019.01.002_bib0500","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1510198","article-title":"Treatment of Fabry's Disease with the Pharmacologic Chaperone Migalastat","volume":"375","author":"Germain","year":"2016","journal-title":"N Engl J Med"}],"container-title":["Archives of Cardiovascular Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213619300397?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1875213619300397?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:45:31Z","timestamp":1761745531000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1875213619300397"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4]]},"references-count":50,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,4]]}},"alternative-id":["S1875213619300397"],"URL":"https:\/\/doi.org\/10.1016\/j.acvd.2019.01.002","relation":{},"ISSN":["1875-2136"],"issn-type":[{"value":"1875-2136","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fabry disease in cardiology practice: Literature review and expert point of view","name":"articletitle","label":"Article Title"},{"value":"Archives of Cardiovascular Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.acvd.2019.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}